{"id":53570,"date":"2023-09-20T09:48:04","date_gmt":"2023-09-20T09:48:04","guid":{"rendered":"https:\/\/medsname.com\/xeloda\/"},"modified":"2026-04-30T16:30:25","modified_gmt":"2026-04-30T16:30:25","slug":"xeloda","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/xeloda\/","title":{"rendered":"Xeloda"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Xeloda<\/strong> \u2014 capecitabine 500 mg (Roche). Oral 5-fluorouracil (5-FU) prodrug \u2014 for adjuvant and metastatic colorectal cancer, breast cancer, gastric cancer, and pancreatic cancer. Bypass IV access. Twice-daily oral schedule.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/li>\n<li>\u03a3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03cc \u03c6\u03ac\u03ba\u03b5\u03bb\u03bf \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/li>\n<li>\u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/li>\n<li>\u0391\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 (<a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03b4\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>\u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2:<\/strong> \u03b1\u03bd \u03b7 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03bc\u03ad\u03c3\u03b1 \u03c3\u03b5 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c4\u03b7\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c0\u03c1\u03cc\u03c3\u03b8\u03b5\u03c4\u03bf \u03ba\u03cc\u03c3\u03c4\u03bf\u03c2. <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\">\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae<\/a>.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Xeloda ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor \u2014 never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specialist-supervised cancer therapy<\/strong> \u2014 this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Hand-foot syndrome (palmar-plantar erythrodysaesthesia)<\/strong><br \/>Common (30-60%) and dose-limiting. Symptoms: tingling, redness, painful fissures, peeling on palms\/soles. Grade 2+ requires dose interruption + reduction. Prophylaxis: emollients, gloves for housework, avoid heat exposure, urea-based creams, vitamin B6 of unproven benefit. Reassess at every cycle.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>DPYD genotype testing recommended<\/strong><br \/>Dihydropyrimidine dehydrogenase (DPD) deficiency causes severe, sometimes fatal toxicity \u2014 neutropenia, mucositis, diarrhoea, neuropathy. Some guidelines now recommend DPYD genotype testing before starting any 5-FU or capecitabine to identify partial\/complete deficiency. If DPD-deficient, dose reduction or alternative therapy is needed.<\/div>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>How is it taken?<\/h3>\n<p>1250 mg\/m\u00b2 twice daily for 14 days, followed by a 7-day rest (3-week cycle). Some regimens use 1000 mg\/m\u00b2 BID \u00d7 14 days. Always specialist-prescribed by body surface area.<\/p>\n<h3>With or without food?<\/h3>\n<p>Within 30 minutes after a meal \u2014 improves tolerability and standardises absorption.<\/p>\n<h3>Common side effects?<\/h3>\n<p>Hand-foot syndrome (very common), diarrhoea, nausea, fatigue, mucositis, hyperbilirubinaemia, mild neutropenia. Severe in DPD-deficient patients.<\/p>\n<h3>\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd;<\/h3>\n<p>Warfarin: capecitabine massively raises INR \u2014 frequent monitoring or switch to LMWH. Phenytoin: raised levels. Folinic acid: can enhance toxicity in some regimens. CYP2C9 substrates: variable interactions.<\/p>\n<h3>Contraindications?<\/h3>\n<p>Severe renal impairment (CrCl &lt;30), severe DPD deficiency, pregnancy, breastfeeding. Caution in moderate renal impairment (dose reduce 25%).<\/p>\n<h3>What if hand-foot syndrome develops?<\/h3>\n<p>Grade 1 (mild redness\/dysaesthesia): continue with topical care. Grade 2 (painful, interfering with function): pause until grade 1, reduce dose 25%. Grade 3 (severe): pause, reduce 50% on resuming.<\/p>\n<h3>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7;<\/h3>\n<p>Strongly contraindicated \u2014 teratogenic. Effective contraception during and for at least 6 months after.<\/p>\n<h3>Renal monitoring?<\/h3>\n<p>Baseline renal function then before each cycle. Dose-adjust for CrCl 30-50 mL\/min. Avoid for CrCl &lt;30.<\/p>\n<h3>Vs IV 5-FU?<\/h3>\n<p>Equivalent or superior efficacy in most settings (X-ACT trial in colorectal). Oral administration is much more convenient and avoids central line complications.<\/p>\n<h3>\u03a4\u03b9 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03b1\u03bd \u03c7\u03ac\u03c3\u03c9 \u03bc\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7;<\/h3>\n<p>Skip the missed dose if &gt;6 hours late. Do not double up. Discuss with your oncology team if multiple doses missed.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Cancer Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/xeloda\/\">Xeloda<\/a> \u2014 capecitabine 500 mg \u2014 oral 5-FU prodrug for breast\/colorectal\/gastric cancers<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/altraz\/\">Altraz<\/a> \u2014 anastrozole 1 mg \u2014 aromatase inhibitor for post-menopausal breast cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/xbira\/\">Xbira<\/a> \u2014 abiraterone 250 mg \u2014 CYP17 inhibitor for metastatic prostate cancer<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zoldria\/\">Zoldria<\/a> \u2014 zoledronic acid IV \u2014 for bone metastases and hypercalcaemia<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 for chemotherapy-induced anaemia<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>\u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd:<\/strong> Cancer therapy is highly individualised. Specific drug, dose, schedule, monitoring, and supportive care must be determined by a qualified oncologist or haematologist based on tumour biology, staging, comorbidities, and goals of care. This information is educational; it does not substitute for professional medical advice.<\/div>","protected":false},"excerpt":{"rendered":"<p>Xeloda (Capecitabine 500 mg) \u2014 Roche oral 5-FU prodrug for breast, colorectal, gastric, and pancreatic cancer. Twice-daily 14-day-on\/7-day-off cycles with hand-foot syndrome management.<\/p>","protected":false},"featured_media":53571,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53570","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/53570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=53570"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/53571"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=53570"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=53570"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=53570"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=53570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}